Novo Nordisk A/S (NYSE:NVO) Holdings Lifted by PFG Investments LLC

PFG Investments LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 8.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,924 shares of the company’s stock after purchasing an additional 1,389 shares during the period. PFG Investments LLC’s holdings in Novo Nordisk A/S were worth $1,542,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Xponance Inc. grew its holdings in Novo Nordisk A/S by 27.6% during the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after purchasing an additional 576 shares during the last quarter. AQR Capital Management LLC lifted its position in Novo Nordisk A/S by 110.5% during the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after acquiring an additional 9,012 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Novo Nordisk A/S by 2.2% in the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after purchasing an additional 2,817 shares during the last quarter. Scientech Research LLC bought a new position in shares of Novo Nordisk A/S in the second quarter worth about $467,000. Finally, Creative Planning lifted its position in shares of Novo Nordisk A/S by 8.8% during the 2nd quarter. Creative Planning now owns 281,596 shares of the company’s stock worth $40,195,000 after purchasing an additional 22,848 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent analyst reports. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $87.45 on Tuesday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $392.43 billion, a P/E ratio of 28.30, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The firm has a 50 day moving average of $95.35 and a 200-day moving average of $114.80. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.